Background: Donor-derived cell free DNA (ddcf DNA) has been reported as a universal noninvasive biomarker for rejection monitoring in heart, kidney, liver, and lung transplantation. Current approaches based on next-generation sequencing for quantification of ddcf DNA, although promising, may be restricted by the requirement for donor material, as donor samples may not be available. Methods: We proposed a novel next-generation sequencing approach without donor-derived material and compared the non-donor-derived approach and the donor-derived approach using simulation testing and 69 clinical specimens. We also evaluated the performance for acute rejection and infection monitoring in lung transplantation. Results: The non-donor-derived approach reached similar efficacy as the donor-derived approach with a significant linear correlation of R 2 = 0.98. The proposed approach without donor-derived material could potentially be used to monitor acute rejection and infection in lung transplantation and may be applied to other types of solid organ transplantation.
Introduction
As the respiratory centre, the lungs require strong abilities for environmental adaptation and immuno-protection against microbial infections. For patients with end-stage lung disease, lung transplantation may constitute the only effective approach and may largely increase life expectancy and substantially improve quality of life [1] . However, despite considerable advances and the wide use of immunosuppressant drugs, acute rejection (AR) remains a highly prevalent major complication of transplantations, especially in the first year post-operationally, impacting 50% to 90% of patients [2] . It is also recognized as one of the risk factors for the development of bronchiolitis obliterans syndrome, which ultimately leads to long-term morbidity and mortality after lung transplantation [3] . However, no reliable serum marker is available to monitor AR after lung transplantation [4] . Transbronchial biopsy, the gold standard for diagnosis, is an invasive procedure that may cause side effects and is limited by inter-observer variability in grading [3] [4] [5] . Apart from rejection, lung transplant recipients are also at risk of infections owing to hypoimmunity and susceptibility to immunosuppressants, poor clearance of airway secretions, impaired cough reflex, and impaired blood flow to the lung graft [6] . Differential diagnosis between rejection and infection after lung transplantation has always been difficult for clinicians, as the symptoms are generally too similar to distinguish. Therefore, there is considerable need for simple and noninvasive approaches for early and accurate lung allograft rejection and/or infectious pathogen test methods.
In 1998, Lo et al. found that there were cell-free donor-derived DNA (ddcfDNA) tags existing in the plasma samples of transplant recipients and that these tags might be used for monitoring graft rejection [7] . Since then, methods based on donor-specific chromosome Y, HLA marker, and single nucleotide polymorphism (SNP) sites from plasma DNA [8] [9] [10] , with the aid of techniques such as digital droplet PCR coamplification at lower denaturation tempera-ture-PCR [11] [12] , quantitative PCR and next-generation sequencing (NGS), had been used for transplantation rejection monitoring of the liver, kidney, heart, and lung [13] [14] [15] [16] [17] . Current approaches for quantification of ddcfDNA that do not obtain massively parallel signatures and do not use donor-derived material such as digital droplet PCR may lead to instability and inconclusive results. Approaches based on SNPs by plasma sequencing could avoid this shortcoming and have shown great potential for application in solid organ transplantation. One of these methods is the genome transplant dynamics (GTD) approach [10] [14] [17] , which used a bead-based system for genotyping from the genomic DNA of pre-transplant donors and recipients to distinguish heterologous SNPs and whole genome sequencing (WGS) from cell-free DNA (cfDNA) of the post-transplant recipient plasma to calculate the donor fraction by a weighted formula. As an essential step of the GTD approach, large-scale use of genotyping arrays would significantly increase the cost of rejection detection [18] . The use of this approach may also be restricted by the need for a donor's genomic DNA information for genotyping, as the policy of privacy protection for donors is strictly enforced, and such donor samples may be lacking in the clinic treating the recipient. Therefore, a NGS-based approach not requiring donor-derived material would greatly enhance transplantation monitoring.
Here, we introduce an non-donor-derived cfDNA transplant dynamics (NDTD) approach that is implemented by genotyping with only genomic DNA from a pre-transplant recipient by targeted capture NGS in a mini-screen SNP array and calculating donor fraction with cell-free DNA from post-transplant recipient samples that contain cfDNA such as plasma and urine by extra-low depth WGS to monitor AR and infection. The scheme of the workflow used to monitor AR by the NDTD approach is shown in Figure 1 . In the current study, ddcfDNA was first used as a biomarker of transplantation by the NGS approach genotyping without donor-derived materials to solve the differentiation between rejection and infection. A specific cut-off value algorithm was established to calculate acute rejection and non-rejection. Then, clinical specimens were brought in for validation. However, large cohorts should be examined for further validation and study. 
DNA Extraction, Library Preparation, and Sequencing
For each time point, 5 ml peripheral blood was collected in an EDTA tube and stored at 4˚C immediately after collection. Plasmas were centrifuged within 4 h following a two-step centrifugation procedure: 1) centrifuge the peripheral blood in a Horizontal centrifuge at 1600 g for 10 minutes at 4˚C, then transfer the supernatant carefully to new 2 ml microcentrifuge tubes, 2) centrifuge the supernatant in a microcentrifuge at 16000 g for 10minutes at 4˚C, then collect the supernatant carefully to new 2ml microcentrifuge tubes and stored at −80˚C.
Cell-free DNA was extracted from 0.5 to 1 ml of plasma by using a QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany); extracted DNA was then quantified using an Agilent 2100 Bioanalyzer (High Sensitivity DNA Kit).
Genomic DNA for genotyping were purified by using a DNeasy blood and tissue kit (Qiagen, Hilden, Germany) and stored at −20˚C.
Purified plasma DNA was prepared into a library following the standard library preparation protocol. For genomic DNA used for genotyping, libraries were captured and enriched according to the manufacturer's protocol. After library preparation, library size distribution and quantification were confirmed using the Agilent Bioanalyzer 2100 and sequencing was performed with a BGISEQ-100 (Thermo Fisher, Proton) or HiSeq 2000 (Illumina, San Diego, CA) instrument.
Genotype Array Design
SNP saturation analysis in two lung transplant patients with three plasma sam- 
Quantification of ddcfDNA
High quality reads were firstly aligned to the human reference genome (UCSC hg19), using BWA or TAMPtools (for BGISEQ-100 sequencing data) with default parameters and then PCR duplications were removed by using SAMtools rmdup or BamDuplicates tools with default parameters. Next, genomic DNA sequencing reads from pre-transplantation recipient samples were genotyped by Without the requirement of genotyping the pre-transplant donor genomic DNA, the predicted probability of a population allele such as reference homozygous P db (AA) , allele homozygous P db (BB), and heterozygous P db (AB) genotype frequencies were calculated in the East Asian population from the 1000 Genomes Project database [20] assuming Hardy-Weinberg equilibrium. calculating donor signal are considered (assuming no sequencing errors). The predicted probability of the donor is equal to the probability of the population allele when conditions 1 and 4are [P(AA) = P db (AA); P(AB) = P db (AB); P(BB) = P db (BB)] and greater than the probability of the population allele owing to the absence of the homozygous allele, which is the same as in the recipient, when conditions 2 and 3 are [P(AB) = P db (AB)/(P(AB) + P(BB)); P(BB) = P db (BB)/(P(AB) + P(BB)); P(AA) = P db (AA)/(P(AB) + P(AA))] ( Table 1) 
Data Analysis of Pathogenic Agents
High quality reads of the sequencing data were primarily aligned using BWA mem tools (-k 32 -M -t 10) to the human reference genome (UCSC hg19). The remaining reads (usually less than 5%) that were unable to map to the human genome were secondarily aligned to the human-related microbe genomics database encompassing viruses, bacteria, fungi, and protozoa, that were mainly collected from National Center for Biotechnology Information (NCBI) genome database autonomously using BWA mem tools (-k 32 -M -t 10). The normalization value of one pathogenic abundance, abu, was calculated according to the formula, [abu = total reads of one pathogenic agent/(millions of mapped reads of all pathogenic agents in the same kingdom × kilobases of pathogenic agent genomic sequence)]. Then, the species taxonomy and gene information identifier was annotated from the NCBI database. Finally, infection event for each recipient was determined with elevated levels of relative abundance, abu, in time-points dynamic monitoring instead of pathogen-specific thresholds to discriminate between colonization, infection, and disease.
Statistical Analysis
Coefficients of determination (R squared) were performed using Excel (Microsoft). Kolmogorov-Smirnov test and Welch's t test were performed in R 2.15.1. A P value of < 0.05 was considered statistically significant. ROC analyses were performed using GraphPad Prism 5.
Results

Evaluation Testing of the NDTD Approach
To check the availability of the mini-screen target capture array, genomic DNA from two healthy volunteers (to simulate pre-transplant recipient and donor, respectively) was extracted and sequenced with mean depth = 1.7 gigabases (Gb), representing 110-fold coverage per sample (see online Supplemental Table  S2 ), by targeted capture NGS in the selected mini-screen SNP array and then 14,804 (which is greater than 10,000) heterologous SNPs were detected by the GTD approach. Synchronously, we defined "0% donor" as the negative control and mixed cell-free DNA of the volunteer "donor" into the "recipient" with the donor DNA fraction varying from 0.5% to 10% to simulate the post-transplant recipient plasma samples. We sequenced eight simulation samples by extra-low depth WGS: mean depth = 1.59 Gb, 0.5-fold mean coverage per sample (see online Supplemental Table S3 ), with 8192 reads average, located at heterologous SNP sites. Finally, the donor fraction was calculated, showing a significant linear correlation (R² = 0.99, Figure 3(a) ) between the calculated donor fraction in the test and the donor percentage in theory, indicating sufficiency to measure organ transplant rejection by the mini-screen target capture array. Next, the donor fraction was re-calculated from the simulation data aban- 
Differentiation of Lung Transplant Rejection by the NDTD Approach
We performed quantification of ddcfDNA to monitor acute rejection and detection of the infectious agents simultaneously by the NDTD approach and com- Table S4 ). However, the difference was not significant between the non-rejection group and the chronic rejection group (P = 0.9340, Welch's t test), implying that additional chronic rejection events should be observed in further studies ( Figure 5 ). According to these results, we may find that ddcfDNA levels from lung allograft recipients increase when rejection events occur, especially during acute rejection.
For detection of infectious agents, whole genome sequencing reads were used Generally, the mean % ddcfDNA in the acute rejection group was higher than that in the non-rejection group and that in the chronic rejection group.
to evaluate the virus, bacteria, and fungus infection concurrently after removing host reads of human sequence. We found positive infection status that was vali- Table S4 ).
Discussion
The distinction between rejection and infection after solid organ transplantation has always presented a problem for clinical therapy because the clinical symptoms are sometimes similar. There is no reliable marker for AR monitoring, which is limited to detecting restricted pathogen species in the clinic; detection of rejection and infection only using the same data from blood samples thus presents an exciting prospect. Our results demonstrate that the NDTD approach without donor-derived material has the ability to monitor acute rejection by quantification of ddcfDNA and to detect the infectious agents simultaneously. 
Conclusion
In conclusion, these findings suggest that the NDTD approach has the ability of diagnosis and discrimination between rejection and infection post-transplant in lung transplantation and may be applied to other types of solid organ transplantation (such as heart, kidney, and liver) where ddcfDNA may also exist in the recipient's plasma. It demonstrates a cost-effective and noninvasive sequencing approach without the requirement of donor-derived genotyping, which will better satisfy the needs of clinical situations and show a wider range of clinical application to accelerate the development of precautionary molecular diagnosis in solid organ transplantation. Table S1 . Lung transplant recipient demographic characteristics. 
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